Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 551

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 4
Chunk 551
---
ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

54

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON
EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Common Stock 

Our common stock trades under the symbol “INMB” on The Nasdaq
Capital Market and has been publicly traded since February 4, 2019. Prior to this time, there was no public market for our common stock.

As of December 31, 2024,
there were 28 holders of record of our common stock. Because shares of our common stock are held by depositories, brokers and other nominees,
the number of beneficial holders of our shares is substantially larger than the number of record holders.

Dividend Policy

We have not declared any cash
dividends on our common stock since inception and do not anticipate paying such dividends in the foreseeable future. We plan to retain
any future earnings for use in our business operations. Any decisions as to future payment of cash dividends will depend on our earnings
and financial position and such other factors as the Board of Directors deems relevant.

Securities Authorized for Issuance Under Equity
Compensation Plans

Information about our equity
compensation plans in Item 12 of Part III of this Annual Report is incorporated herein by reference.

Recent Sales of Unregistered Equity Securities

None. 

Issuer Purchases of Equity Securities 

None.

ITEM 6. [RESERVED]

ITEM 7.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and
analysis of our financial condition and results of operations in conjunction with our financial statements and notes thereto appearing
elsewhere in this Annual Report. In addition to historical financial information, the following discussion and analysis contains forward-looking
statements that involve risks, uncertainties, and assumptions. Our actual results could differ materially from those anticipated by these
forward-looking statements as a result of many factors. We discuss factors that we believe could cause or contribute to these differences
below and elsewhere in this Form 10-K, including those set forth under “Risk Factors” and “Forward-Looking Statements.”

Overview

Our objective is to develop
and commercialize our product candidates to treat diseases where the innate immune system is dysfunctional causing or contributing to
the patient’s disease. Innate immune dysfunction can occur for a variety of reasons including genetics, lifestyle, and